Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cardiovascular Research

• Publication date

  2005-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.CARDIORES.2004.11.013PMID 15820196
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones

  2004cited by this paper
• Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction.

  2004cited by this paper
• Evidence for a Causal Role of the Renin-Angiotensin System in Vascular Dysfunction Associated With Insulin Resistance

  2004cited by this paper
• Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study.

  2004cited by this paper
• Oxidative Stress Activates the Plasminogen Activator Inhibitor Type 1 (PAI-1) Promoter through an AP-1 Response Element and Cooperates with Insulin for Additive Effects on PAI-1 Transcription*

  2004cited by this paper
• Association of functional thrombin‐activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population

  2004cited by this paper
• Increased expression of plasminogen activator inhibitor-1 with fibrin deposition in a murine model of aging, "klotho" mouse

  2003cited by this paper
• Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease.

  2003cited by this paper
• Thrombin‐activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system

  2003cited by this paper
• Aging Increases Aortic MMP‐2 Activity and Angiotensin II in Nonhuman Primates

  2003cited by this paper
• Acute Release of Plasminogen Activator Inhibitor-1 in ST-Segment Elevation Myocardial Infarction Predicts Mortality

  2003cited by this paper
• Aging accelerates endotoxin-induced thrombosis : increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging.

  2002cited by this paper
• Aging and Thrombosis

  2002cited by this paper
• Plasminogen activator inhibitor-1 is a major stress-regulated gene: Implications for stress-induced thrombosis in aged individuals

  2002influential reference
• Age-Dependent Spontaneous Coronary Arterial Thrombosis in Transgenic Mice That Express a Stable Form of Human Plasminogen Activator Inhibitor-1

  2002cited by this paper
• Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway.

  2002cited by this paper
• Increased Expression of Plasminogen Activator Inhibitor-1 with Fibrin Deposition in a Murine Model of Aging, "Klotho" Mouse

  2002cited by this paper
• Altered Regulation of Matrix Metalloproteinase-2 in Aortic Remodeling During Aging

  2002cited by this paper
• The Tissue Factor and Plasminogen Activator Inhibitor Type-1 Response in Pediatric Sepsis-induced Multiple Organ Failure

  2002cited by this paper
• Aging and obesity augment the stress-induced expression of tissue factor gene in the mouse.

  2002cited by this paper
• Obesity and the risk of heart failure.

  2002cited by this paper
• Genetic Mechanisms of Age Regulation of Protein C and Blood Coagulation* 210

  2002cited by this paper
• Age-Related Reduction of NO Availability and Oxidative Stress in Humans

  2001cited by this paper
• Nitric oxide insufficiency, platelet activation, and arterial thrombosis.

  2001cited by this paper
• Augmented Age-associated Innate Immune Responses Contribute to Negative Inotropic and Lusitropic Effects of Lipopolysaccharide and Interferon γ

  2001cited by this paper
• Plasminogen activator inhibitor‐1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin

  2001cited by this paper
• Plasminogen Activator Inhibitor-1 Deficiency Prevents Hypertension and Vascular Fibrosis in Response to Long-term Nitric Oxide Synthase Inhibition

  2001cited by this paper
• Augmented age-associated innate immune responses contribute to negative inotropic and lusitropic effects of lipopolysaccharide and interferon gamma.

  2001cited by this paper
• Angiotensin II type 1 receptor−153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects

  2001cited by this paper
• Aging, Carotid Artery Distensibility, and the Ser422Gly Elastin Gene Polymorphism in Humans

  2001cited by this paper
• Plasminogen-activator inhibitor type 1 and coronary artery disease.

  2000cited by this paper
• Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.

  2000cited by this paper
• Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors

  2000cited by this paper
• Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?

  2000cited by this paper
• Insulin Continues to Induce Plasminogen Activator Inhibitor 1 Gene Expression in Insulin-Resistant Mice and Adipocytes

  2000cited by this paper
• Sympathetic nervous system activity and α-adrenergic responsiveness in older hypertensive humans.

  1999cited by this paper
• Genetic mechanisms of age regulation of human blood coagulation factor IX.

  1999cited by this paper
• The natural course of atherosclerosis. Part II: vascular remodeling. Bruneck Study Group.

  1999cited by this paper
• Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1

  1999cited by this paper
• Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1.

  1999cited by this paper
• Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure

  1999cited by this paper
• Correlates of Antithrombin, Protein C, Protein S, and TFPI in a Healthy Elderly Cohort

  1998cited by this paper
• Alterations of nitric oxide synthase expression with aging and hypertension in rats.

  1998cited by this paper
• Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.

  1998cited by this paper
• Natural anticoagulants, aging, and thromboembolism.

  1998cited by this paper
• A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders.

  1998cited by this paper
• The Pathophysiologic Roles of Interleukin-6 in Human Disease

  1998cited by this paper
• Cardiac senescence is associated with enhanced expression of angiotensin II receptor subtypes.

  1998cited by this paper
• Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography.

  1997cited by this paper
• Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators.

  1997cited by this paper
• Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men.

  1997cited by this paper
• Mutation of the mouse klotho gene leads to a syndrome resembling ageing

  1997cited by this paper
• Coagulation factor VII and the risk of coronary heart disease in healthy men.

  1997cited by this paper
• Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation

  1997cited by this paper
• Elevated Expression of Transforming Growth Factor-β in Adipose Tissue from Obese Mice

  1997cited by this paper
• Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty

  1996cited by this paper
• Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease.

  1996cited by this paper
• Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide.

  1996cited by this paper
• Increase of Plasminogen Activator Inhibitor Levels Predicts Outcome of Leukocytopenic Patients with Sepsis

  1996cited by this paper
• Association of chronic stress with plasminogen activator inhibitor-1 in healthy middle-aged men.

  1996cited by this paper
• Stressful events as a trigger of sudden death: a study of 43 medico-legal autopsy cases.

  1996cited by this paper
• Tissue Distribution and Regulation of Plasminogen Activator Inhibitor-1 in Obese Mice

  1996cited by this paper
• Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities.

  1996cited by this paper
• Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator.

  1996cited by this paper
• The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase.

  1995cited by this paper
• Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.

  1995cited by this paper
• Hypercoagulability in centenarians: the paradox of successful aging.

  1995influential reference
• Plasminogen Activator Inhibitor-1 (PAI-1) Promoter Polymorphism and Coronary Artery Disease in Non-Insulin-Dependent Diabetes

  1995cited by this paper
• Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.

  1995cited by this paper
• Murine CD14 gene expression in vivo: extramyeloid synthesis and regulation by lipopolysaccharide

  1995cited by this paper
• Determinants of Plasminogen Activator Inhibitor 1 Activity in Treated NIDDM and Its Relation to a Polymorphism in the Plasminogen Activator Inhibitor 1 Gene

  1995cited by this paper
• Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction.

  1995cited by this paper
• Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis.

  1995cited by this paper
• Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

  1995cited by this paper
• Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.

  1994cited by this paper
• Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction.

  1994cited by this paper
• Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.

  1994cited by this paper
• Factors Responsible for Impaired Fibrinolysis in Obese Subjects and NIDDM Patients

  1994cited by this paper
• Plasminogen Activator Inhibitor-1 Expression in Human Liver and Healthy or Atherosclerotic Vessel Walls

  1994cited by this paper
• In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons.

  1994cited by this paper
• Factor VII and Fibrinogen Levels as Risk Factors for Venous Thrombosis

  1994cited by this paper
• Age-related changes in the hemostatic system

  1993cited by this paper
• The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.

  1993cited by this paper
• Associations of Factor VIII and von Willebrand Factor with Age, Race, Sex, and Risk Factors for Atherosclerosis

  1993cited by this paper
• Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.

  1993cited by this paper
• High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.

  1993cited by this paper
• Thrombosis and cardiovascular risk in the elderly.

  1992cited by this paper
• Substrate-bound fibrinogen, fibrin and other cell attachment-promoting proteins as a scaffold for cultured vascular smooth muscle cells.

  1992cited by this paper
• Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation.

  1992cited by this paper
• The distribution of coagulation factors VII and VIII and fibrinogen in adults over 65 years. Results from the Cardiovascular Health Study.

  1992cited by this paper
• Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.

  1992cited by this paper
• On the Fibrinolytic System in Aged Rats, and Its Reactivity to Endotoxin and Cytokines

  1992cited by this paper
• Plasminogen activator inhibitor-1 messenger RNA expression is induced in rat hepatocytes in vivo by dexamethasone.

  1992cited by this paper
• Thrombosis and cardiovascular risk in the elderly.

  1992cited by this paper
• On measuring instability in demography

  1991cited by this paper
• Increased susceptibility of aged rats to haemorrhage and intravascular hypercoagulation following endotoxin administered in a generalized Shwartzman regime

  1991cited by this paper
• Obesity, fat distribution and cardiovascular disease.

  1991cited by this paper
• Elevated plasminogen activator inhibitor levels found in patients with malignant conditions.

  1991cited by this paper
• Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.

  1991cited by this paper
• Activation of neurohumoral systems following acute myocardial infarction.

  1991cited by this paper

• 4G/5G polymorphism and plasma levels of plasminogen activator inhibitor-1 in essential thrombocythemia patients with driver mutational status

  2026cites this paper
• Toll-like receptor 2 drives liver senescence and fibrosis in aging through gut-derived microbial signaling.

  2026cites this paper
• Multicentre development and validation of a risk model integrating immunotherapy and coagulation biomarkers for thrombosis in autoimmune neurological disorders.

  2026cites this paper
• PAI-1 is a common driver of aging and diverse diseases

  2025cites this paper
• Nutraceutical COMP-4 confers protection against endothelial dysfunction through the eNOS/iNOS-NO-cGMP pathway

  2025cites this paper
• Endothelial Dysfunction and Hemostatic System Activation in Relation to Shift Workers, Social Jetlag, and Chronotype in Female Nurses

  2025cites this paper
• Mechanisms of endothelial senescence and vascular aging

  2025cites this paper
• The significance of PAI-1 expression in chronic diseases: from metabolic syndrome, emotional stress and chronic kidney disease to aging

  2025cites this paper
• Role of plasminogen activator inhibitor-1 (PAI-1) in age-related cardiovascular pathophysiology.

  2025cites this paper
• Plasminogen activator Inhibitor-1 in systemic sclerosis: A nexus of fibrosis, vasculopathy, and senescence

  2025cites this paper
• Von Willebrand factor and von Willebrand disease in ageing: mechanisms, evolving phenotypes, and clinical implications.

  2025cites this paper
• A 3D Human Neuron-on-Chip Platform to Monitor Neuronal Injury Responses

  2025cites this paper
• CircMYO9A inhibits influenza A virus replication by dampening haemagglutinin cleavage via increasing SERPINE1/PAI-1 expression

  2025cites this paper
• Lyophilized MSC-EVs attenuates COVID-19 pathogenesis by regulating the JAK/STAT pathway

  2025cites this paper
• Insulin Resistance, Hyperinsulinemia and Atherosclerosis: Insights into Pathophysiological Aspects and Future Therapeutic Prospects

  2024cites this paper
• Molecular and Functional Alterations in the Cerebral Microvasculature in an Optimized Mouse Model of Sepsis-Associated Cognitive Dysfunction

  2024cites this paper
• Impact of Plasminogen Activator Inhibitor-1 Serum Levels and the -675 4G/5G Variant in the SERPINE1 Gene on Systemic Sclerosis in a Mexican Population

  2024cites this paper
• Unconventional localization of PAI-1 in PML bodies: A possible link with cellular growth of endothelial cells

  2024cites this paper
• CO-Induced TTP Activation Alleviates Cellular Senescence and Age-Dependent Hepatic Steatosis via Downregulation of PAI-1

  2023cites this paper
• Glucocorticoid-Responsive Tissue Plasminogen Activator (tPA) and Its Inhibitor Plasminogen Activator Inhibitor-1 (PAI-1): Relevance in Stress-Related Psychiatric Disorders

  2023cites this paper
• Treatment of stroke in aged male and female rats with Vepoloxamer and tPA reduces neurovascular damage

  2023cites this paper
• How I treat von Willebrand disorders in the elderly.

  2023cites this paper
• Inflammation as an exacerbation marker and target for prophylaxis against Coronavirus Disease 2019-related thrombosis

  2023cites this paper
• The risk for post-thrombotic syndrome of subjects with deep vein thrombosis in an Indonesian referral hospital: a retrospective cohort study

  2023cites this paper
• Aging, Plasminogen Activator Inhibitor 1, Brain Cell Senescence, and Alzheimer’s Disease

  2023cites this paper
• PAI-1 Regulation of p53 Expression and Senescence in Type II Alveolar Epithelial Cells

  2023cites this paper
• The Human Extracellular Matrix Diseasome Reveals Genotype–Phenotype Associations with Clinical Implications for Age-Related Diseases

  2023cites this paper
• Thrombosis and Aging: Fibrin Clot Properties and Oxidative Stress

  2023cites this paper
• Plasma‐Derived Nanoclusters for Site‐Specific Multimodality Photo/Magnetic Thrombus Theranostics

  2023cites this paper
• Cold atmospheric plasma-enabled platelet vesicle incorporated iron oxide nano-propellers for thrombolysis

  2023cites this paper
• Involvement of plasminogen activator inhibitor-1 in p300/p53-mediated age-related atrial fibrosis

  2023cites this paper
• Perioperative glycemic status is linked to postoperative complications in non-intensive care unit patients with type-2 diabetes: a retrospective study

  2022cites this paper
• Age-Related Increase of Collagen/Fibrin Deposition and High PAI-1 Production in Human Nasal Polyps

  2022cites this paper
• PAI-1: A Major Player in the Vascular Dysfunction in Obstructive Sleep Apnea?

  2022cites this paper
• Commentary on “The suboptimal fibrinolytic response in COVID‐19 is dictated by high PAI‐1”

  2022cites this paper
• The mechanistic basis linking cytokine storm to thrombosis in COVID-19

  2022cites this paper
• The Molecular Mechanisms of Intestinal Inflammation and Fibrosis in Crohn’s Disease

  2022cites this paper
• Promising protein biomarkers in the early diagnosis of Alzheimer’s disease

  2022cites this paper
• Circadian Rhythms and Acute Coronary Syndrome in the Elderly.

  2022cites this paper
• Aging, Cellular Senescence, and Alzheimer’s Disease

  2022cites this paper
• Review of evidence implicating the plasminogen activator system in blood-brain barrier dysfunction associated with Alzheimer’s disease

  2022cites this paper
• The pathophysiology of chronic subdural hematoma revisited: emphasis on aging processes as key factor

  2022cites this paper
• Biomarkers associated with coronary high-risk plaques

  2022cites this paper
• Electronic Cigarette Exposure Causes Vascular Endothelial Dysfunction Due to NADPH Oxidase Activation and eNOS Uncoupling.

  2022cites this paper
• The Aging Heart: A Molecular and Clinical Challenge

  2022cites this paper
• Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge

  2021cites this paper
• DNAm-based signatures of accelerated aging and mortality in blood are associated with low renal function

  2021cites this paper
• Fibrinolysis in Patients with Liver Disease

  2021cites this paper
• COVID-19 Vasculopathy: Mounting Evidence for an Indirect Mechanism of Endothelial Injury

  2021cites this paper
• Small Airways Disease, Biomarkers and COPD: Where are We?

  2021cites this paper
• Coagulation and wound repair during COVID-19

  2021cites this paper
• COPD_A_280157 351..365

  2021cites this paper
• The plasminogen activating system in the pathogenesis of Alzheimer’s disease

  2021cites this paper
• Divergent Regulation of Alveolar Type 2 Cell and Fibroblast Apoptosis by Plasminogen Activator Inhibitor 1 in Lung Fibrosis

  2021cites this paper
• The Central Role of Fibrinolytic Response in COVID-19—A Hematologist’s Perspective

  2021cites this paper
• How to manage bleeding disorders in aging patients needing surgery.

  2021cites this paper
• The Plasminogen–Activator Plasmin System in Physiological and Pathophysiological Angiogenesis

  2021cites this paper
• Postmortem pathological changes in extrapulmonary organs in SARS-CoV-2 rt-PCR–positive cases: a single-center experience

  2021cites this paper
• Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19

  2021cites this paper
• Polypharmacy Frequency: The Relationship Between Polypharmacy and Mortality in COVID-19 (+) Older Adults

  2021cites this paper
• Comorbidity-associated glutamine deficiency is a predisposition to severe COVID-19

  2021cites this paper
• The aging venous system: from varicosities to vascular cognitive impairment

  2021cites this paper
• Silibinin as potential tool against SARS‐Cov‐2: In silico spike receptor‐binding domain and main protease molecular docking analysis, and in vitro endothelial protective effects

  2021cites this paper
• Lifelong dietary omega-3 fatty acid suppresses thrombotic potential through gut microbiota alteration in aged mice

  2021cites this paper
• Visceral fat‐specific regulation of plasminogen activator inhibitor‐1 in aged septic mice

  2021cites this paper
• Antithrombotic strategies in elderly patients with acute coronary syndrome.

  2021cites this paper
• A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease

  2021cites this paper
• Porphyromonas gingivalis Gingipains-Mediated Degradation of Plasminogen Activator Inhibitor-1 Leads to Delayed Wound Healing Responses in Human Endothelial Cells

  2021cites this paper
• Risk factors of thrombosis in Chinese subjects with acute promyelocytic leukemia

  2021cites this paper
• Cerebral venous thrombosis in COVID-19

  2021cites this paper
• Association of PAI-1 rs2227631 Variant and Clinical Factors with Recurrent Myocardial Infarction in Patients with Coronary Artery Disease

  2020cites this paper
• Increased dipeptidyl peptidase-4 accelerates chronic stress-related thrombosis in a mouse carotid artery model.

  2020cites this paper
• Hematology and hemostasis in the pediatric, geriatric, and pregnant populations

  2020cites this paper
• Unbiased proteomics identifies plasminogen activator inhibitor-1 as a negative regulator of endothelial nitric oxide synthase

  2020cites this paper
• A serine protease secreted from Bacillus subtilis cleaves human plasma transthyretin to generate an amyloidogenic fragment

  2020cites this paper
• Thromboembolic disease: a geriatric syndrome

  2020cites this paper
• TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer

  2020cites this paper
• Dysregulation of Pulmonary Responses in Severe COVID-19

  2020cites this paper
• Carbofuran accelerates the cellular senescence and declines the life span of spns1 mutant zebrafish

  2020cites this paper
• PAI-1, the Plasminogen System, and Skeletal Muscle

  2020cites this paper
• 1 IBERIAN CURED-HAM CONSUMPTION IMPROVES ENDOTHELIAL 2 FUNCTION IN HEALTHY SUBJECTS 3 4

  2020cites this paper
• Impaired ECM Remodeling and Macrophage Activity Define Necrosis and Regeneration Following Damage in Aged Skeletal Muscle

  2020cites this paper
• Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad

  2020cites this paper
• Postmortem examination of COVID‐19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction

  2020cites this paper
• Cell non-autonomous regulation of health and longevity

  2020cites this paper
• An aberrant STAT pathway is central to COVID-19

  2020cites this paper
• Platelets in aging and cancer—“double-edged sword”

  2020cites this paper
• Increased expression of plasminogen activator inhibitor-1 (PAI-1) is associated with depression and depressive phenotype in C57Bl/6J mice

  2019cites this paper
• Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists.

  2019cites this paper
• Biophysics and Neurophysiology of the Sixth Sense

  2019cites this paper
• The Physical Burden of Immunoperception

  2019cites this paper
• The Physiopathological Crossroads of Aging

  2019influential citation
• Immunohistochemical expression of plasminogen activator inhibitor-1 in subcutaneous versus omental adipose tissue in patients after elective abdominal surgery

  2019cites this paper
• Endothelial PPARγ Is Crucial for Averting Age-Related Vascular Dysfunction by Stalling Oxidative Stress and ROCK

  2019cites this paper
• Plasminogen Activator Inhibitor Type‐1 as a Regulator of Fibrosis

  2018cites this paper
• Hemostasis and Thrombosis in the Oldest Old

  2018cites this paper
• Stress/inflammation and pai-1 as stellar processes in the aging and associated pathologies

  2018cites this paper
• Hematological Changes with Aging

  2017cites this paper
• Vehicle-dependent Effects of Sphingosine 1-phosphate on Plasminogen Activator Inhibitor-1 Expression

  2017cites this paper
• The beneficial effects of aerobic and concurrent training on metabolic profile and body composition after detraining: a 1-year follow-up in postmenopausal women

  2017cites this paper